DNA vaccines onward and upward! 20 years and counting! Highlights of the DNA Vaccines 2012 Meeting

References

• Kichaev G, Mendoza JM, Amante D, Smith TR, McCoy JR, Sardesai NY, Broderick KE. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25272; PMID: 23954979
   PubMed Web of Science ®Google Scholar
• Almansour I, Chen H, Wang S, Lu S. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25735; PMID: 23884239
   PubMed Web of Science ®Google Scholar
• Moise L, Tassone R, Latimer H, Terry F, Levitz L, Haran JP, Ross TM, Boyle C, Martin WD, De Groot AS. Immunization with cross-conserved H1N1 influenza CD4(+) T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.26511; PMID: 24045788
   PubMed Web of Science ®Google Scholar
• Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, Yu L, Guan Y, Shen X, Tomaras GD, Labranche C, et al. Vaccination with Vaxfectin (®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25442; PMID: 23820294
   PubMed Web of Science ®Google Scholar
• Kulkarni V, Rosati M, Bear J, Pilkington GR, Jalah R, Bergamaschi C, Singh AK, Alicea C, Chowdhury B, Zhang GM, et al. Comparison of intradermal and intramuscular delivery followed in vivo electroporation of SIV Env DNA in macaques. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25473; PMID: 23811579
   PubMed Web of Science ®Google Scholar
• Wallace A, West K, Rothman AL, Ennis FA, Lu S, Wang S. Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.26009; PMID: 23941868
   PubMed Web of Science ®Google Scholar
• Nowroozalizadeh S, Gudmundsdotter L, Hejdeman B, Andersson L, Esbjörnsson J, Medstrand P, Sandström E, Gaines H, Wahren B, Jansson M. Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25154; PMID: 23912942
   PubMed Web of Science ®Google Scholar
• Isaguliants M, Smirnova O, Ivanov AV, Kilpelainen A, Kuzmenko Y, Petkov S, Latanova A, Krotova O, Engström G, Karpov V, et al. Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme’s performance in gene immunization. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25813; PMID: 23881028
   PubMed Web of Science ®Google Scholar
• Gil A, Shen S, Coley S, Gibson L, Diamond DJ, Wang S, Lu S. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25750; PMID: 24051429
   PubMed Web of Science ®Google Scholar
• Wu B, Zou Q, Hu Y, Wang B. Interleukin-22 as a molecular adjuvant facilitates IL-17-producing CD8 (+) T-cell responses against a HBV DNA vaccine in mice. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.26047; PMID: 23941891
   PubMed Web of Science ®Google Scholar
• Hokey DA, Ginsberg A. The current state of tuberculosis vaccines. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25427; PMID: 23792698
   PubMed Web of Science ®Google Scholar
• Burgain A, Rochard A, Trollet C, Mazuet C, Popoff MR, Escriou V, Scherman D, Bigey P. DNA electroporation in rabbits as a method for generation of high-titer neutralizing antiserum: Examples of the botulinum toxins types A, B, and E. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25192; PMID: 23877030
   PubMed Web of Science ®Google Scholar
• Zhang C, Jin K, Xiao Y, Cheng Y, Huang Z, Wang S, Lu S. Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25656; PMID: 23851482
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Maiolatesi S, Fedders C, Reyes S, Reyes A, Vasquez C, Alcorta Y, Chuang I, Spring M, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.24941; PMID: 23899517
   PubMed Web of Science ®Google Scholar
• Whittemore K, Sykes K. A microarray method for identifying tumor antigens by screening a tumor cDNA expression library against cancer sera. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25634; PMID: 23851590
   PubMed Web of Science ®Google Scholar
• Ligtenberg MA, Rojas-Colonelli N, Kiessling R, Lladser ANF. -κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25699; PMID: 23884215
   PubMed Web of Science ®Google Scholar
• Liu H, Geng S, Feng C, Xie X, Wu B, Chen X, Zou Q, Wang S, Cui J, Xing R, et al. A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8(+)T lymphocytes in a murine melanoma model. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25013; PMID: 24051432
   PubMed Web of Science ®Google Scholar
• Reschner A, Scohy S, Vandermeulen G, Daukandt M, Jacques C, Michel B, Nauwynck H, Xhonneux F, Préat V, Vanderplasschen A, et al. Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25086; PMID: 24051431
   PubMed Web of Science ®Google Scholar
• Nelson J, Rodriguez S, Finlayson N, Williams J, Carnes A. Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25048; PMID: 23899469
   PubMed Web of Science ®Google Scholar
• Coban C, Kobiyama K, Jounai N, Tozuka M, Ishii KJ. DNA vaccines: A simple DNA sensing matter?. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25893; PMID: 23912600
   PubMed Web of Science ®Google Scholar
• Rosli R, Nograles N, Hanafi A, Nor Shamsudin M, Abdullah S. Mucosal genetic immunization through microsphere-based oral carriers. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25325; PMID: 24051430
   PubMed Web of Science ®Google Scholar
• Petkov SP, Heuts F, Krotova OA, Kilpelainen A, Engström G, Starodubova ES, Isaguliants MG. Evaluation of immunogen delivery by DNA immunization using non-invasive bioluminescence imaging. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25561; PMID: 23896580
   PubMed Web of Science ®Google Scholar
• Li J, Geng S, Liu X, Liu H, Jin H, Liu CG, Wang B. DNA and protein co-administration induces tolerogenic dendritic cells through DC-SIGN mediated negative signals. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25011; PMID: 24051433
   PubMed Web of Science ®Google Scholar
• Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.24702; PMID: 24051434
   PubMed Web of Science ®Google Scholar
• Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.26498; PMID: 24045230
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. A novel, disruptive vaccination technology: Self-adjuvanted RNActive (®) vaccines. Hum Vaccin Immunother 2013; 9; Forthcoming http://dx.doi.org/10.4161/hv.25181; PMID: 23921513
   PubMed Web of Science ®Google Scholar